Antifungal Medications

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Terbinafine Hydrochloride is an oral synthetic allylamine broad-spectrum fungicidal agent on the WHO Model List of Essential Medicines. It non-competitively inhibits squalene epoxidase, an essential early enzyme in fungal ergosterol biosynthesis. This induces intracellular accumulation of toxic squalene and depletion of ergosterol, causing fungal cell membrane lysis. Highly lipophilic and keratophilic, accumulating in stratum corneum, hair follicles, and nails. Indicated for tinea unguium (onychomycosis of toenails/fingernails), extensive tinea corporis/cruris, and severe tinea pedis.

Griseofulvin Tablets 250 mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Ketoconazole topical cream (2% w/v) is a broad-spectrum imidazole antifungal agent. It disrupts fungal cell membranes by inhibiting 14-alpha-demethylase, eradicating dermatophytes, Candida species, and Malassezia yeasts. Indicated for tinea corporis, tinea cruris, tinea pedis, cutaneous candidiasis, and pityriasis versicolor.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Sertaconazole Nitrate (2% w/w cream or dusting powder) is a third-generation broad-spectrum imidazole antifungal containing a benzothiophene ring. It features a unique dual mechanism: fungistatic action (inhibition of ergosterol synthesis) combined with direct fungicidal action (benzothiophene intercalation into fungal cell membranes, forming pores and causing lethal leakage of intracellular adenosine triphosphate). Indicated for tinea pedis (interdigital athlete's foot), tinea corporis, tinea cruris, and cutaneous candidiasis.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Luliconazole (1% w/w) is an advanced chiral imidazole antifungal agent containing an exclusive (R)-enantiomer with a dithiolane core. It exhibits exceptionally low minimum inhibitory concentrations (MICs) against dermatophytes (Trichophyton rubrum, T. mentagrophytes), achieving fungicidal tissue concentrations in the stratum corneum that persist long after treatment cessation. Indicated for tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Amorolfine Hydrochloride (0.25% cream or 5% nail lacquer) is a morpholine-class broad-spectrum fungicidal agent. It inhibits two distinct sequential enzymes in fungal sterol biosynthesis: delta-14-reductase and delta-7,8-isomerase, depleting ergosterol and causing accumulation of atypical ignosterol in fungal membranes. Nail lacquer forms a non-water-soluble lacquer film that penetrates the nail plate to the nail bed, maintaining high antifungal concentrations for over a week. Indicated for distal and lateral subungual onychomycosis (without matrix involvement) and superficial dermatomycoses.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Eberconazole Cream 1% is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Luliconazole (1% w/w) is an advanced chiral imidazole antifungal agent containing an exclusive (R)-enantiomer with a dithiolane core. It exhibits exceptionally low minimum inhibitory concentrations (MICs) against dermatophytes (Trichophyton rubrum, T. mentagrophytes), achieving fungicidal tissue concentrations in the stratum corneum that persist long after treatment cessation. Indicated for tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Clotrimazole (1% w/w cream, lotion, or dusting powder) is a versatile broad-spectrum imidazole antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase, depleting ergosterol and increasing fungal cell permeability. Dusting powder formulation absorbs excess moisture in intertriginous skin folds, preventing fungal maceration. Indicated for tinea pedis, tinea cruris, tinea corporis, cutaneous candidiasis, and prevention of recurrence in sweaty body folds.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Ketoconazole topical cream (2% w/v) is a broad-spectrum imidazole antifungal agent. It disrupts fungal cell membranes by inhibiting 14-alpha-demethylase, eradicating dermatophytes, Candida species, and Malassezia yeasts. Indicated for tinea corporis, tinea cruris, tinea pedis, cutaneous candidiasis, and pityriasis versicolor.

Sertaconazole Nitrate (2% w/w cream or dusting powder) is a third-generation broad-spectrum imidazole antifungal containing a benzothiophene ring. It features a unique dual mechanism: fungistatic action (inhibition of ergosterol synthesis) combined with direct fungicidal action (benzothiophene intercalation into fungal cell membranes, forming pores and causing lethal leakage of intracellular adenosine triphosphate). Indicated for tinea pedis (interdigital athlete's foot), tinea corporis, tinea cruris, and cutaneous candidiasis.

Terbinafine Hydrochloride topical formulation is a fungicidal allylamine antifungal. It inhibits squalene epoxidase in fungal cell membranes, causing rapid fungal cell death. Highly effective against dermatophytes (Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum). Indicated for tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Itraconazole is a synthetic triazole broad-spectrum antifungal on the WHO Model List of Essential Medicines. It inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), blocking conversion of lanosterol to ergosterol and destabilizing the fungal cell membrane. Features high lipophilicity and keratin affinity, persisting in nails for months after completion. Indicated for onychomycosis, dermatophytosis refractory to topical therapy, pityriasis versicolor, systemic aspergillosis, histoplasmosis, blastomycosis, and candidiasis.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.

Fluconazole is a synthetic bistriazole antifungal agent on the WHO Model List of Essential Medicines. It selectively inhibits fungal lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis with 100-fold higher affinity for fungal enzymes than human CYP450. Features exceptional water solubility, high oral bioavailability (>90%), and long half-life (around 30 hours). Indicated for vaginal candidiasis, mucosal candidiasis (oropharyngeal, esophageal), cryptococcal meningitis, tinea pedis/corporis/cruris, and candidal prophylaxis in immunocompromised patients.